Nuvalent reports Q4 net loss $38.3M; cash $719.9M; NVL-520 gets FDA BTD

Nuvalent, Inc.

2023-FY EPS reported -$2.17

Cash, cash equivalents and marketable securities $719.9M at Dec 31, 2023; operating runway into 2027.
Q4 net loss $38.3M, full year 2023 net loss $126.2M; R&D expenses $35.6M Q4 and $113.2M full year.
FDA granted Breakthrough Therapy Designation to NVL-520 for ROS1+ NSCLC after 2+ prior TKIs.
Initiated Phase 2 of ALKOVE-1 trial for NVL-655 at 150 mg once daily with registrational intent.
Expect to initiate Phase 1 for HER2 program in 2024; promoted Matthew Metivier to SVP HR.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Nuvalent, Inc. reported the quarter and year ended December 31, 2023 results: net income Net loss was $38.3 million for the fourth quarter of 2023 and $126.2 million for the year ended December 31, 2023..

Period: the quarter and year ended December 31, 2023
Net income: Net loss was $38.3 million for the fourth quarter of 2023 and $126.2 million for the year ended December 31, 2023.
Result: reported results

Exact text from the filing

On February 27, 2024, Nuvalent, Inc. announced its financial results for the quarter and year ended December 31, 2024, and other corporate updates.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Nuvalent, Inc. reported the fourth quarter of 2023 and the year ended December 31, 2023 results: net income Net loss was $38.3 million for the fourth quarter of 2023 and $126.2 million for the year ended December 31, 2023..

Period: the fourth quarter of 2023 and the year ended December 31, 2023
Net income: Net loss was $38.3 million for the fourth quarter of 2023 and $126.2 million for the year ended December 31, 2023.
Result: reported results

Exact text from the filing

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Nuvalent, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-020604

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.